References | Country | Study design | Mean age (years) total or case/control | Patient source | Sepsis/control (n) | Total (n) | Proportion of patients with sepsis (%) | Assay method | Cutoff | Sensitivity, specificity | TP (n) | FP (n) | FN (n) | TN (n) |
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Davis et al. [18] | USA | Prosp | – | EDs | 38/62 | 100 | 38.0 | In-house | 2000 MESF | 0.88, 0.71 | 33 | 18 | 5 | 44 |
Livaditi et al. [19] | Greece | Prosp | – | ICUs | 47/12 | 59 | 79.7 | In-house | 2566 mol/cell | 0.95, 1.00 | 44 | 0 | 3 | 12 |
Cardelli et al. [20] | Italy | Retro | 63 | ICUs | 52/60 | 112 | 46.4 | In-house | 2398Â mol/cell | 0.96, 0.95 | 50 | 3 | 2 | 57 |
Hsu et al. [21] | China | Prosp | 67/80 | ICUs | 55/11 | 66 | 83.3 | In-house | 4300Â mol/cell | 0.89, 0.96 | 49 | 1 | 6 | 10 |
Gamez-Diaz et al. [22] | Colombia | Prosp | – | EDs | 404/206 | 610 | 66.2 | Leuko64 kit | 1.7 MESF | 0.66, 0.65 | 266 | 73 | 138 | 133 |
Gibot et al. [23] | France | Prosp | 61/60 | ICUs | 154/146 | 300 | 51.3 | In-house | 1.62 | 0.84, 0.95 | 130 | 7 | 24 | 139 |
Gros et al. [24] | France | Prosp | 61/58 | ICUs | 148/145 | 293 | 50.5 | Leuko64 kit | 2.2 | 0.63, 0.89 | 93 | 16 | 55 | 129 |
Gerrits et al. [25] | Netherlands | Not described | 74/69 | ICUs | 25/19 | 44 | 56.8 | Leuko64 kit | 1.66 | 1.00, 0.95 | 25 | 1 | 0 | 18 |
Dimoula et al. [26] | Belgium | Prosp | 61/58 | ICUs | 103/365 | 468 | 22.0 | In-house | 230 MFI | 0.89, 0.87 | 92 | 47 | 11 | 318 |
Righi et al. [27] | Italy | Prosp | 59/58 | ICUs | 61/32 | 93 | 65.6 | In-house | 2000 ABC | 0.90, 0.97 | 55 | 1 | 6 | 31 |
Godnic et al. [28] | Germany | Retro | – | ICUs | 40/7 | 47 | 85.1 | Leuko64 kit | 1.95 | 0.76, 0.75 | 30 | 1 | 10 | 6 |
Bauer et al. [29] | USA | Prosp | 66/59 | ICUs | 110/86 | 196 | 54.8 | In-house | 1040.5Â mol/cell | 0.76, 0.77 | 84 | 20 | 26 | 66 |
Muzlovic et al. [30] | Slovenia | – | – | ICUs | 25/7 | 32 | 78.1 | Leuko64 kit | 1.58 | 1.00, 0.86 | 25 | 1 | 0 | 6 |
Tan et al. [31] | Malaysia | Prosp | – | EDs | 42/9 | 51 | 82.4 | In-house | 45 ABC | 0.81, 0.89 | 34 | 1 | 8 | 8 |